

Valuation of Biotech Companies

Philipp Alena

Dr. Meinrad Good

Dr. Wolfgang Knecht

Dr. Markus Scheidegger

Management Weiterbildung

Universität Zürich

Table of Content

Abstract	5
1. Introduction	6
1.1. The Biotech Industry	6
1.2. Valuation of Biotech Companies	6
2. Characteristics of the Biotech Industry	8
2.1. Overview of Drug Development Process	8
2.1.1. Pre-Clinical Studies	10
2.1.2. Clinical Studies	10
2.1.3. Marketing Application	12
2.2. The first Critical Valuation Procedure: Due Diligence	13
2.2.1. Product/Market Analysis	14
2.2.2. Management	16
2.2.3. Financial Resources	16
3. Financial Assessment of Projects and Enterprises	17
3.1. Overview of Basic Concepts	17
3.2. Illustration Example	18
3.3. Approaches Based on Future Economic Profit	19
3.3.1. Discounted Cash Flow	19
3.3.2. Economic Value Added	23
3.3.3. Option Pricing Methods	27
3.4. Book Values and Traditional Methods	30
3.5. The Method of Comparables (Multiples)	32
4. Valuation of the Late Stage Biotech Company BioMarin	34
4.1. Overview of the Company	34
4.2. IPO Valuation Process and Assumptions	35
4.2.1. Development Projects	35
4.2.2. Consolidated Financial Data Estimates	36
4.2.3. Valuation	37
4.3. Post IPO Development and Relative Performance	39
4.3.1. Development of Stock Price	39
4.3.2. Revision of Estimates	42
4.3.3. Conclusion of the valuation approach in practice	43
5. Conclusions	43
6. References	45
Appendix A: The Black-Scholes Formula	47
Appendix B: Glossary	48

About the Authors

Philipp Alena

completed his education as securities trader after passing his commercial apprenticeship. Following stays in Paris and New York, he completed the Swiss Banking School program. In his professional career he was jointly responsible for establishing Vontobel Securities in New York. Upon his return to Zurich he was appointed deputy head of Bondtrading at Bank Vontobel. He has been responsible for the Fixed Income department of the bank since 1997.

Meinrad Good

is a Biochemist and received his Ph.D. from the University of Zurich. He has extensive knowledge and experience in the pharmaceutical industry as Medical Director, Head of Marketing and Sales, and Consultant. He is now an entrepreneur and established the Pharma & Biotech consulting company BPB in 1994, currently named Target BioScience Ltd.

Wolfgang Knecht

received a Master of Science degree in physics from the Massachusetts Institute of Technology (MIT) and a Ph.D. in Technical Science from the Swiss Federal Institute of Technology (ETH) Zurich. From 1995 to 1998 Dr. Knecht worked at Phonak R&D designing noise reduction concepts for the first generation of digital hearing instruments. Since 1998 he has been the Managing Director of the Neuroscience Center Zurich, a joint research center of the University and ETH Zurich.

Markus Scheidegger

received his Master degree in Electrical Engineering and a Ph.D. in Technical Science from the Swiss Federal Institute of Technology (ETH) Zurich. He was engaged in medical research for the University of Alabama in Birmingham, USA, and again for the ETH Zurich. Since 1998 he has been employed as modality manager for magnetic resonance systems at Philips medical systems in Zurich.